logo
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

Yahoo23-05-2025
Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma, or PDAC. As of April 25, 2025, patients in the dose level 1 cohort, which was selected as the recommended Phase 2 dose, achieved an overall response rate of 83% – 10/12 -. As of April 25, 60 patients had been treated in one of five dose regimens with the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in frontline metastatic PDAC. In the dose level 1 cohort, 12 patients received 2.4 mg of avutometinib twice a week, 200 mg of defactinib twice a day for 3 weeks out of every 4 and 800 mg/m2 of gemcitabine and 125 mg/m2 of Nab-paclitaxel on a schedule of day 1, day 8 and day 15. In dose level 1, 83% of patients achieved partial responses.The company has selected dose level 1 as the RP2D, has met the pre-defined criteria to advance beyond the first stage of the expansion study, and is now enrolling up to 29 patients at this dose level. In evaluating all the dose cohorts, dose level 1 demonstrated the highest response rate and across all five dose cohorts, 92% of efficacy evaluable patients showed tumor reduction as best response. No new safety signals have emerged. While anticipating results from the study expansion cohort, the company is now developing plans for a registrational Phase 3 front-line metastatic PDAC trial to begin in 2026.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on VSTM:
Disclaimer & DisclosureReport an Issue
Verastem's Strategic Focus and FDA Approval Drive Buy Rating
Verastem files to sell 3.43M shares of common stock for holders
Verastem reports Q1 adjusted EPS (79c), two estimates (77c)
Verastem price target raised to $13 from $12 at B. Riley
Verastem's Market Potential Boosted by Accelerated Approval of AVMAPKI FAKZYNJA for KRAS Mutant LGSOC
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Fastest Van' At the Nurburgring: Ford Stock (NYSE:F) Slips Despite Outlandish Win
'Fastest Van' At the Nurburgring: Ford Stock (NYSE:F) Slips Despite Outlandish Win

Business Insider

time7 hours ago

  • Business Insider

'Fastest Van' At the Nurburgring: Ford Stock (NYSE:F) Slips Despite Outlandish Win

Give legacy automaker Ford (F) credit: it is taking the credo of 'no boring cars' so seriously that it is almost frightening. In fact, Ford managed to make a Transit SuperVan surprisingly, well, surprising by putting it to the test on the Nurburgring track. It came away from that storied proving ground with a new record: the fastest van to ever see the track. Yet despite this, Ford stock slipped fractionally in Monday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It was considered iconic when the Ford Transit van, driven by Sabine Schmitz on an episode of Top Gear, managed to post a lap time of 10:12. But recently, Romain Dumas took a similar run in Ford's electric vehicle (EV) demonstrator version of the SuperVan and pared over three minutes off Schmitz's time. The SuperVan came in at 6:48.42, which—and brace yourself for this—puts it between Chevrolet's (GM) Corvette ZR1X and a late-model representative from the Mercedes-AMG (MBGAF) GT Black Series. Admittedly, there were key differences that helped; the SuperVan made its run on slick tires, and was built as a 'purpose-built racing vehicle.' This forces observers to take the result with something of a grain of salt, even if the lap is still downright impressive by any standard for something that looks like, well, a van. Consider the 2025 Explorer With the end of the model year approaching, some car buyers are, perhaps, starting to wonder if they should buy a new car now or wait for the next model year to show up. And for the Ford Explorer—one of Ford's biggest names in SUV—that model year issue is particularly telling. The 2026 Explorer, reports note, will actually be less expensive than the 2025 model. Several new Explorers will be part of the lineup, including the Explorer Active at $38,330, the Platinum at $50,830, and the Tremor, taking over for the Timberline, that costs $48,330. But the 2025 models are often seeing price cuts, reports note, part of a clear-the-lot strategy. And in some cases, the 2025s may have better feature sets, which means a 2025 could prove a better value than its 2026 equivalent. Is Ford Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Hold consensus rating on F stock based on two Buys, nine Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 6.72% rally in its share price over the past year, the average F price target of $10.74 per share implies 6% downside risk.

Lendlease Group (LLESF) Receives a Hold from UBS
Lendlease Group (LLESF) Receives a Hold from UBS

Business Insider

time8 hours ago

  • Business Insider

Lendlease Group (LLESF) Receives a Hold from UBS

UBS analyst Tom Bodor maintained a Hold rating on Lendlease Group today and set a price target of A$5.90. The company's shares closed last Friday at $3.60. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bodor covers the Real Estate sector, focusing on stocks such as BWP Trust, Centuria Industrial REIT, and Lifestyle Communities Ltd. According to TipRanks, Bodor has an average return of -2.2% and a 53.78% success rate on recommended stocks. In addition to UBS, Lendlease Group also received a Hold from Morgan Stanley's Simon Chan in a report issued today. However, on the same day, Citi maintained a Buy rating on Lendlease Group (Other OTC: LLESF). The company has a one-year high of $5.30 and a one-year low of $2.86. Currently, Lendlease Group has an average volume of 1,251.

This Is Why Jim Cramer Is Bullish on IBM Stock
This Is Why Jim Cramer Is Bullish on IBM Stock

Business Insider

time8 hours ago

  • Business Insider

This Is Why Jim Cramer Is Bullish on IBM Stock

On a recent episode of his show, CNBC's Jim Cramer shared his thoughts on tech giant IBM (IBM) after a caller asked for his opinion. He said that the company's most recent earnings report wasn't bad at all and suggested that its current share price might present a good buying opportunity. Interestingly, what really stood out to Cramer was IBM's leadership in quantum computing, which he believes will soon become a much bigger topic among tech investors. He also highlighted IBM's strong software lineup and noted that the company is doing many things right across the tech space. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It is worth noting that Cramer's optimism seems justified. Indeed, the company recently developed a new algorithm called Relay-BP that was designed to help quantum computers detect and fix errors more effectively. This is a major step forward because quantum systems use qubits, which are units of information that are highly sensitive to outside interference. Notably, Relay-BP proved to be up to 10 times more accurate than earlier techniques, and it runs more efficiently by using less computing power. This makes it more practical for real-world applications. As a result, the company plans to first use the algorithm to stabilize quantum memory and then expand its use to a wider range of quantum operations. While this likely isn't a final solution, it does move the industry much closer to making scalable, everyday quantum computing a reality. Therefore, this progress seems to support Cramer's view that IBM is well-positioned for the future, especially in areas like quantum computing. Is IBM a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, six Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $296.15 per share implies 23.7% upside potential.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store